NASDAQ:ICCC ImmuCell (ICCC) Stock Price, News & Analysis $11.33 -0.09 (-0.79%) Closing price 04:00 PM EasternExtended Trading$11.22 -0.11 (-0.97%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About ImmuCell Stock (NASDAQ:ICCC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ImmuCell alerts:Sign Up Key Stats Today's Range$10.79▼$11.7350-Day Range$9.58▼$11.4252-Week Range$4.52▼$12.10Volume18,535 shsAverage Volume12,701 shsMarket Capitalization$102.99 millionP/E Ratio57.10Dividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview ImmuCell is an animal health company focused on products for cattle. It develops, manufactures and markets products intended to support the health of dairy and beef herds. Its best-known product line, First Defense, consists of oral antibody products given to newborn calves to help protect against common causes of scours, a form of calf diarrhea. The products are designed to provide targeted antibodies during the early stages of life. ImmuCell has also developed Re-Tain, a non-antibiotic product for subclinical mastitis in dairy cows. The company is based in Portland, Maine, and has a history of developing antibody-based products for animal health.AI Generated. May Contain Errors. Read More ImmuCell Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks23rd Percentile Overall ScoreICCC MarketRank™: 1.145861059355 of 5 starsImmuCell scored higher than 23% of companies evaluated by MarketBeat, and ranked 792nd out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingImmuCell has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageImmuCell has only been the subject of 1 research reports in the past 90 days.Read more about ImmuCell's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmuCell is 57.10, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.44.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmuCell is 57.10, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.76.Price to Book Value per Share RatioImmuCell has a P/B Ratio of 3.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.17% of the float of ImmuCell has been sold short.Short Interest Ratio / Days to CoverImmuCell has a short interest ratio ("days to cover") of 2.79, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ImmuCell has recently decreased by 18.76%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmuCell does not currently pay a dividend.Dividend GrowthImmuCell does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.94 News SentimentImmuCell has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for ImmuCell this week, compared to 2 articles on an average week. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ImmuCell insiders have not sold or bought any company stock.Percentage Held by Insiders5.70% of the stock of ImmuCell is held by insiders.Percentage Held by Institutions13.47% of the stock of ImmuCell is held by institutions.Read more about ImmuCell's insider trading history. Receive ICCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmuCell and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ICCC Stock News HeadlinesImmuCell Corp (ICCC) Q3 2026 Earnings Call Highlights: 46% Sales Surge and Return to ProfitabilityNovember 13, 2026 | finance.yahoo.comImmuCell (ICCC) Q3 2026 Earnings Call TranscriptNovember 13, 2026 | fool.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.November 17 at 1:00 AM | Base Camp Trading (Ad)ImmuCell Corporation (ICCC) Q3 2026 Earnings Call TranscriptNovember 13, 2026 | seekingalpha.comImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2026November 12, 2026 | globenewswire.comImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2026November 6, 2026 | markets.businessinsider.comImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2026November 6, 2026 | globenewswire.comImmuCell Q3 Preliminary Sales RiseOctober 13, 2026 | finance.yahoo.comSee More Headlines ICCC Stock Analysis - Frequently Asked Questions How have ICCC shares performed this year? ImmuCell's stock was trading at $6.15 at the beginning of 2026. Since then, ICCC stock has increased by 84.2% and is now trading at $11.33. How were ImmuCell's earnings last quarter? ImmuCell Corporation (NASDAQ:ICCC) issued its earnings results on Thursday, November, 12th. The biotechnology company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.05. The biotechnology company earned $8.04 million during the quarter, compared to the consensus estimate of $5.40 million. ImmuCell had a trailing twelve-month return on equity of 6.25% and a net margin of 5.66%. Read the conference call transcript. Who are ImmuCell's major shareholders? ImmuCell's top institutional investors include Mink Brook Asset Management LLC (2.24%) and State Street Corp (0.15%). Insiders that own company stock include David Scott Tomsche and Boekhorst Paul Francis Oliv Te. View institutional ownership trends. How do I buy shares of ImmuCell? Shares of ICCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ImmuCell own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuCell investors own include CRISPR Therapeutics (CRSP), MARA (MARA), Novavax (NVAX), Neurocrine Biosciences (NBIX), Aqua Metals (AQMS), Boxlight (BOXL) and Cleanspark (CLSK). Company Calendar Last Earnings11/12/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ICCC's financial health is in the Green zone, according to TradeSmith. ICCC has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ICCC CIK811641 Webwww.immucell.com Phone(207) 878-2770Fax207-878-2117Employees73Year Founded1982Profitability EPS (Trailing Twelve Months)$0.20 Trailing P/E Ratio57.10 Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.04 million Net Margins5.66% Pretax Margin5.79% Return on Equity6.25% Return on Assets4.15% Debt Debt-to-Equity Ratio0.20 Current Ratio4.61 Quick Ratio2.50 Sales & Book Value Annual Sales$27.64 million Price / Sales3.73 Cash Flow$0.19 per share Price / Cash Flow59.23 Book Value$3.61 per share Price / Book3.14Miscellaneous Outstanding Shares9,090,000Free Float8,573,000Market Cap$102.99 million OptionableNot Optionable Beta0.61 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:ICCC) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuCell Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuCell With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.